Cancer Immunotherapy Market Worth $152.83 Billion By 2024
On the basis of product type, monoclonal antibodies segment commanded the largest share of the global cancer immunotherapy market in 2017. However, checkpoint inhibitors market is expected to grow at the fastest CAGR during the forecast period, owing to high success rate of PD-1 & PD-L1 drugs and increasing pipelines of biotechnology and pharmaceutical companies with combination therapies for anti-PD-1 and PD-L1 inhibitors. Moreover, cell therapy market is also expected to witness significant growth through 2024. Development of new and effective therapy options to cure symptoms of the disease is a key factor contributing to growth of cell therapy market.
Browse in-depth Report on - https://www.meticulousresearch.com/product/cancer-immunotherapy-market/
On the basis of application, cancer immunotherapy market for lung cancer application commanded the largest share of the global market in 2017. Major factors propelling the growth of cancer immunotherapy market in lung cancer application are growing incidence, mortality rate, and benefits of immunotherapy to the lung cancer patients; whereas, cancer immunotherapy market for multiple myeloma applications expected to witness the highest growth rate during the forecast period. The approval of innovative caner immunotherapy for the treatment of multiple myeloma has increased the adoption of immunotherapies in treatment of multiple myeloma. Moreover, recognizing the potential of immunotherapy in multiple myeloma, major players in immunotherapy market such as Celgene, Amgen, Janssen, and Juno Therapeutics engaged in multiple collaborations to evaluate certain drug entities for the treatment of multiple myeloma.
On the basis of end user, hospitals dominated the global market. This is mainly attributed to the rise in healthcare spending which has resulted in the increasing use of immunotherapeutic drugs in hospitals and the large number of patients being treated in hospitals for cancer immunotherapy; however, clinics and other end user markets are expected to witness a rapid growth during the forecast period with the increasing number of clinics providing cancer immunotherapy, and rising number of ongoing clinical trials for immunotherapy drugs.
Request for a sample of this research report @ - https://www.meticulousresearch.com/download-sample-report/cp_id=4690
This research report analyzes major geographies and provides comprehensive analysis of North America (U.S., Canada), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, and RoAPAC), Latin America, and Middle East & Africa. North America commanded the largest share of the global cancer immunotherapy market in 2017, followed by Europe and Asia Pacific. However, Asia Pacific region is expected to grow at a higher CAGR during the forecast period. Growth in this market is expected to be driven by large pool of patient population seeking the cancer treatment, increasing prevalence of cancer, aggressive investment by the major players in the market, increasing government spending on the healthcare, and increasing disposable income of the population that improved the access to cancer treatment. Furthermore, lack of stringent regulations and liberalization in Asian countries is also a key factor making Asia Pacific a lucrative market.
The major players operating in the global cancer immunotherapy market are F. Hoffmann-La Roche (Switzerland), Celgene Corporation (US), Bristol-Myers Squibb (US), Merck & Co., Inc. (US), and Amgen Inc. (US),ELI Lilly and Company (US), Janssen Global Services, LLC (US) (Johnson and Johnson), Novartis (Switzerland), Pfizer, Inc. (US), Gilead Sciences, Inc. (US), Dendreon Pharmaceuticals (US), and Bayer (Germany) among others.
Contact Sales- +1-646-781-8004
Office No-202, 203,204,205,206;
2nd Floor, Pushpak Business Hub,
Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, with the help of its unique research methodologies, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa regions.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cancer Immunotherapy Market Worth $152.83 Billion By 2024 here
News-ID: 1767347 • Views: 226
More Releases from Meticulous Research®
Radiotherapy Market Worth $10.15 billion by 2025 at a CAGR of 5.6% from 2019 to …
Meticulous Research® – leading global market research company published a research report titled “Radiotherapy Market by Product (Radiotherapy devices, Software, Service), By Procedure (EBRT, Brachytherapy, Systemic Radiotherapy), By Technology (IMRT, SRT, VMAT, HDRBT, LDRBT, PDRBT), By Application (Prostate, Breast) – Global Forecasts to 2025”. Download a Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5023 According to this latest publication from Meticulous Research®, the global radiotherapy market is expected to grow at a CAGR
The Future Of Telehealth | Telemedicine Market : What Covid19 impact does this h …
Meticulous Research® –leading global market research company published a research report titled “Telehealth market/Telemedicine Market by Component (Service, Software, Device), Mode of Delivery (On premise, Web, Cloud), Application (Radiology, Cardiology, Primary/Urgent Care, ICU, Mental Health), End User (Physician, Payor, Patient) — Global Forecast to 2023”. According to this latest publication from Meticulous Research®, the global telehealth market is expected to grow at a CAGR of 23.0% from 2018 to 2023 to
Smart Cities Market Analysis, Post Covid-19 Impact | Potential Business Impacts …
Meticulous Research® — a leading global market research company published a research report titled “Smart Cities Market by Application (Smart Utilities, Smart Transportation, Water Management, Waste Management, Smart Healthcare, Smart Lighting, Smart Education), Component (Hardware, Software, and Services), and Geography- Global Forecast to 2027”. According to this latest publication from Meticulous Research®, the Smart Cities Market is expected to grow at a CAGR of 22.9% from 2019 to reach $545.7 billion
Pre & Post COVID-19 Market Estimates- Ventilators Market Worth $7.72 billion by …
According to a new market research report “Ventilators Market by Product (Instruments, Accessories), Mobility (Intensive Care, Portable), Interface (Invasive, Non-invasive), Age Group (Adult, Pediatric), Mode (Volume, Pressure, Dual), End User (Hospital, ASCs, Home Care) — Global Forecast to 2027”, published by Meticulous Research, the ventilators market is expected to grow at a CAGR of 15.8% from 2020 to reach $7.72 billion by 2027. Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5093 Ventilatory intervention
More Releases for Asia
RAMPF Korea – Producing in Asia for Asia
Joint Venture for the Asian markets – The international RAMPF Group has realigned the cooperation with its long-standing partner Orient Dosiertechnik from Korea with the founding of RAMPF Korea Co., Ltd. The new company based in Hwaseong City is developing and producing mixing and dispensing systems specifically for the Asian markets. Within the framework of the new joint venture based in Hwaseong City, mixing and dispensing systems are being developed and
LIXIL Asia Presents Asia Pacific Property Awards
Through its power brands GROHE and American Standard, LIXIL Asia signs a three-year deal to become the Headline Sponsor of the Asia Pacific Property Awards from 2019 until 2022. 23rd January 2019: The International Property Awards, first established in 1993, are open to residential and commercial property professionals from around the globe. They celebrate the highest levels of achievement by companies operating within the architecture, interior design, real estate and property
MES: Expansion in Asia
Berlin, November 24, 2014: Model Engineering Solutions (MES), the Berlin-based specialist for model-based software development, has significantly expanded its business in Asia. In recent years, MES has built up a network of local partners in Japan, Korea, China, and India in order to benefit from the growing market and increasing interest in model-based development and ISO 26262 in Asia. Asia: Driving force in the automotive industry The automotive industry continues
Undersea Defence Technology Asia, UDT Asia 2011
Latest Military Diving Technologies featured in UDT Asia Equipping Asia’s navies with the latest diving technology for asymmetric warfare and operations SINGAPORE, 17 October 2011 - Naval diving and underwater special operations is a field that is seeing increased attention and investment amongst navies in Asia. Units such as the Indonesian Navy‟s KOPASKA, the Republic of Singapore Navy‟s Naval Diving Unit (NDU), the Royal Malaysian Navy‟s PASKAL are increasingly utilising specialised equipment for conducting
UDT Asia 2011
Clarion Events hosts the Undersea Defence Technology (UDT) Asia 2011 conference and exhibition to bring senior naval and industry personnel together to cover underwater developments in the region Singapore, May 30 – Clarion Events is hosting UDT Asia on 30 November – 1 December 2011. The event brings together the undersea defence community in Asia, featuring top regional naval speakers, who will be addressing the latest underwater requirements for Asian navies. According
eltherm goes Asia
Finally all preparations are finished and the new subsidiary of eltherm GmbH, eltherm Asia Pacific Pte Ltd has commenced operations in Singapore on 1st April 2010. To celebrate the starting shot, an opening celebration was held in the afternoon of 28th July in the office premises followed by a get together dinner and drinks in the evening at a pub. A total of 62 guests attended the event with the